Cotellic (cobimetinib) and Zelboraf (vemurafenib) is an oral BRAF and MEK inhibitor combination therapy for the treatment of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.
If you have a Hayes login, click here to view the full report on the Knowledge Center.